Open AccessComparison of oral and intravenous N-acetyl cysteine in preventing contrast nephropathy
Author(s) -
Mohammad Reza Khatami,
Nasrin Nikravan,
Mojtaba Salarifar,
Hamid Reza Poorhosseini,
Saeid Sadeghian,
Ali Mohammad Haj-Zeinali,
Hassan Aghajani
Publication year - 2020
Publication title -
indian journal of nephrology/indian journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 24
eISSN - 1998-3662
pISSN - 0971-4065
DOI - 10.4103/ijn.ijn_260_19
Subject(s) - medicine , placebo , contrast induced nephropathy , nephropathy , kidney disease , creatinine , randomized controlled trial , adverse effect , acetylcysteine , clinical trial , incidence (geometry) , gastroenterology , surgery , pathology , endocrinology , biochemistry , chemistry , alternative medicine , physics , antioxidant , optics , diabetes mellitus
Despite high rates of morbidity and mortality in patients with contrast-induced nephropathy (CIN), there is no consensus regarding prevention of this well-known complication of contrast media use. One agent that has been widely used in this regard is N-acetyl cysteine (NAC). Nevertheless, its efficacy is still controversial. The aim of this study was to assess the efficacy of NAC, both in the oral and intravenous forms, for the prevention of CIN.